ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1871

Myositis-Specific Antibodies and Muscle Histopathology in Juvenile Dermatomyositis: New Insights into the Mechanism of Injury

MaiLan Nguyen1, Vy Do 1, Paul Yell 1, Chanhee Jo 2, Jie Liu 2, Tracey Wright 3 and Chunyu Cai 1, 1University of Texas Southwestern Medical Center, Dallas, TX, 2Texas Scottish Rite Hospital for Children, Dallas, TX, 3University of Texas Southwestern, Texas Scottish Rite Hospital for Children, Children's Health, Dallas, TX

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: histopathologic and autoantibodies, Idiopathic Inflammatory Myopathies (IIM), inflammatory myositis, juvenile dermatomyositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M113: Muscle Biology, Myositis & Myopathies I (1866–1871)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Myositis-specific antibodies (MSAs) are identified in over half of children with JDM and are associated with distinct clinical phenotypes. MSA subtype, in combination with clinical or muscle histopathology findings, may have prognostic value and implications for disease monitoring and treatment. The aim of this study is to define the relationships between MSAs and muscle histopathology as well as clinical markers of disease activity in children with JDM.

Methods: A retrospective chart review of subjects with JDM followed in the pediatric rheumatology clinic at a single center between October 2016 and November 2018 was performed. Markers of JDM disease activity, including muscle enzymes (creatine kinase (CK), aldolase, lactate dehydrogenase, aspartate aminotransferase, and alanine transaminase) and other clinical data were obtained at the initial visit and at 6 months. MSA serum levels were measured at a single point during the disease course. Muscle biopsy samples, routinely obtained at diagnosis, were reviewed and scored independently by 2 neuropathologists using a visual analog scale. Mann-Whitney tests were conducted to detect differences between the most prevalent MSA subtypes. Pearson correlation coefficient (r) was conducted to analyze the correlation between MSA subtype and CK.

Results: Out of the 43 subjects in the study, 26 (60.5%) had a detectable MSA. The most common MSAs were anti-NXP-2 (13, 30.2%), anti-Mi-2 (7, 16.3%), and anti-MDA-5 (5, 11.6%). Other MSAs detected included anti-SRP, anti-Tif-1g, anti-OJ, and anti-PL-7. 

Subjects with high titer anti-Mi-2 had more widespread perifascicular myofiber damage and perifascicular necrotizing myopathy (Figure 1). Subjects with high titer anti-NXP-2 had more prominent capillary C5b-9 deposition, indicative of vascular injury, and myofibers showed perifascicular atrophy and/or focal infarct but minimal perifascicular myofiber necrosis (Figure 2). All subjects with anti-MDA-5 had normal CK and normal muscle histology, consistent with previous reports of amyopathic or hypomyopathic disease. The subject with anti-PL-7 showed perifascicular necrotizing myopathy with diffuse MHC-1 upregulation on histopathology, consistent with the pattern seen in antisynthetase syndrome. 

High titer anti-Mi-2 correlates with serum CK > 10,000 (r=0.96, p=0.002) (Figure 3). With the exception of a subject with anti-PL-7, no other MSA subtypes had a CK > 5000 at the initial visit. Anti-Mi-2 had a higher CK at initial visit compared to anti-NXP-2 (p=0.04) and anti-MDA-5 (p=0.05). In general, anti-Mi-2 was significantly associated with higher muscle enzymes, except for aldolase. There is no correlation between anti-NXP-2 titer and CK (r=-0.21, p=0.49) (Figure 3).

Conclusion: The mechanism of injury for patients with JDM differs based on MSA subtype: anti-Mi-2 is associated with direct myofiber damage; anti-NXP-2 is associated with vascular injury; and anti-MDA-5 is associated with minimal to no muscle injury. Serum CK, a clinical marker of disease activity, varies based on MSA subtype: anti-Mi-2 titer correlates with serum CK; anti-NXP-2 titer does not correlate with serum CK; and anti-MDA-5 is associated with normal serum CK.

Figure 1. Twelve-year-old female with high anti-Mi-2 serum titer; quadriceps muscle shows prominent perifascicular necrotizing myopathy.
-A- H&E shows abundant necrotic and regenerating fibers concentrated in perifascicular region.
-B- MHC-1 is upregulated in perifascicular myofibers.
-C- C5b-9 highlights necrotic fibers. There is no significant capillary deposition.
-D- Alkaline phosphatase shows strong reactivity in regenerating fibers as well as in perimysial and endomysial connective tissue.

Figure 2. Two-year-old female with high anti-NXP-2 serum titer; thigh muscle shows prominent perifascicular atrophy, capillary C5b-9 deposition, and infarct.
-A- H&E shows prominent perifascicular atrophy without significant myofiber necrosis.
-B- MHC-1 is upregulated in perifascicular myofibers.
-C- C5b-9 shows prominent capillary C5b-9 deposition.
-D- Alkaline phosphatase shows no regenerating fibers or connective tissue reactivity.
-E-F- Focal area of infarction is highlighted by C5b-9 stain -E- and alkaline phosphatase -F-. The area of infarct is located in the center of a fascicle, and is composed of back-to-back, rather than scattered, necrotic fibers.

Figure 3.
-left- Anti-Mi-2 titer strongly correlates with serum CK -r=0.96; p=0.002- and degree of myofiber damage.
-right- Anti-NXP-2 titer does not correlate with serum CK -r=-0.21; p=0.49-.


Disclosure: M. Nguyen, None; V. Do, None; P. Yell, None; C. Jo, None; J. Liu, None; T. Wright, None; C. Cai, None.

To cite this abstract in AMA style:

Nguyen M, Do V, Yell P, Jo C, Liu J, Wright T, Cai C. Myositis-Specific Antibodies and Muscle Histopathology in Juvenile Dermatomyositis: New Insights into the Mechanism of Injury [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/myositis-specific-antibodies-and-muscle-histopathology-in-juvenile-dermatomyositis-new-insights-into-the-mechanism-of-injury/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/myositis-specific-antibodies-and-muscle-histopathology-in-juvenile-dermatomyositis-new-insights-into-the-mechanism-of-injury/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology